Cellectis S.a. (CLLS)

$2.5

-0.12

(-4.57%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Cellectis S.a.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 178.0K → 155.0K (in $), with an average decrease of 12.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -10.64M → -17.48M (in $), with an average decrease of 64.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 15.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 333.7%

Performance

  • $2.48
    $2.57
    $2.50
    downward going graph

    0.8%

    Downside

    Day's Volatility :3.31%

    Upside

    2.53%

    downward going graph
  • $0.96
    $3.77
    $2.50
    downward going graph

    61.49%

    Downside

    52 Weeks Volatility :74.46%

    Upside

    33.69%

    downward going graph

Returns

PeriodCellectis S.a.Sector (Health Care)Index (Russel 2000)
3 Months
-7.43%
1.9%
0.0%
6 Months
149.5%
10.7%
0.0%
1 Year
35.74%
4.6%
-1.1%
3 Years
-86.93%
14.2%
-22.1%

Highlights

Market Capitalization
190.0M
Book Value
$1.37
Earnings Per Share (EPS)
-1.41
PEG Ratio
0.0
Wall Street Target Price
7.43
Profit Margin
0.0%
Operating Margin TTM
-1257.3%
Return On Assets TTM
-18.78%
Return On Equity TTM
-71.28%
Revenue TTM
24.5M
Revenue Per Share TTM
0.47
Quarterly Revenue Growth YOY
-12.5%
Gross Profit TTM
24.0M
EBITDA
-62.8M
Diluted Eps TTM
-1.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.27
EPS Estimate Next Year
-1.12
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Cellectis S.a.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 197.2%

Current $2.50
Target $7.43

Company Financials

FY18Y/Y Change
Revenue
12.7M
↓ 49.46%
Net Income
-78.7M
↓ 20.81%
Net Profit Margin
-618.12%
↓ 223.61%
FY19Y/Y Change
Revenue
15.2M
↑ 19.32%
Net Income
-90.7M
↑ 15.24%
Net Profit Margin
-597.01%
↑ 21.11%
FY20Y/Y Change
Revenue
73.9M
↑ 386.83%
Net Income
-72.6M
↓ 19.98%
Net Profit Margin
-98.14%
↑ 498.87%
FY21Y/Y Change
Revenue
73.9M
↑ 0.0%
Net Income
-86.3M
↑ 18.89%
Net Profit Margin
-116.68%
↓ 18.54%
FY22Y/Y Change
Revenue
19.2M
↓ 74.08%
Net Income
-98.7M
↑ 14.38%
Net Profit Margin
-514.78%
↓ 398.1%
FY23Y/Y Change
Revenue
16.5M
↓ 13.95%
Net Income
-85.0M
↓ 13.86%
Net Profit Margin
-515.34%
↓ 0.56%
Q2 FY22Q/Q Change
Revenue
1.3M
↓ 20.57%
Net Income
-18.9M
↓ 40.63%
Net Profit Margin
-1.4K%
↑ 474.88%
Q3 FY22Q/Q Change
Revenue
217.0K
↓ 83.9%
Net Income
-24.7M
↑ 30.23%
Net Profit Margin
-11.4K%
↓ 9965.41%
Q4 FY22Q/Q Change
Revenue
16.0M
↑ 7284.33%
Net Income
-25.7M
↑ 4.16%
Net Profit Margin
-160.4%
↑ 11210.57%
Q1 FY23Q/Q Change
Revenue
139.0K
↓ 99.13%
Net Income
-30.1M
↑ 17.01%
Net Profit Margin
-21.6K%
↓ 21475.57%
Q2 FY23Q/Q Change
Revenue
178.0K
↑ 28.06%
Net Income
-10.6M
↓ 64.59%
Net Profit Margin
-6.0K%
↑ 15653.95%
Q3 FY23Q/Q Change
Revenue
155.0K
↓ 12.92%
Net Income
-17.5M
↑ 64.18%
Net Profit Margin
-11.3K%
↓ 5296.69%
FY17Y/Y Change
Total Assets
332.9M
↑ 0.67%
Total Liabilities
47.0M
↓ 17.05%
FY18Y/Y Change
Total Assets
500.8M
↑ 50.46%
Total Liabilities
50.6M
↑ 7.64%
FY19Y/Y Change
Total Assets
467.5M
↓ 6.66%
Total Liabilities
112.0M
↑ 121.48%
FY20Y/Y Change
Total Assets
469.5M
↑ 0.43%
Total Liabilities
160.6M
↑ 43.42%
FY21Y/Y Change
Total Assets
382.1M
↓ 18.62%
Total Liabilities
145.6M
↓ 9.35%
FY22Y/Y Change
Total Assets
261.2M
↓ 31.63%
Total Liabilities
135.3M
↓ 7.09%
Q2 FY22Q/Q Change
Total Assets
320.9M
↓ 7.58%
Total Liabilities
140.4M
↓ 2.62%
Q3 FY22Q/Q Change
Total Assets
279.6M
↓ 12.87%
Total Liabilities
134.0M
↓ 4.56%
Q4 FY22Q/Q Change
Total Assets
261.2M
↓ 6.57%
Total Liabilities
135.3M
↑ 0.98%
Q1 FY23Q/Q Change
Total Assets
251.4M
↓ 3.75%
Total Liabilities
130.9M
↓ 3.22%
Q2 FY23Q/Q Change
Total Assets
227.7M
↓ 9.44%
Total Liabilities
131.1M
↑ 0.15%
Q3 FY23Q/Q Change
Total Assets
209.7M
↓ 7.89%
Total Liabilities
133.6M
↑ 1.88%
FY18Y/Y Change
Operating Cash Flow
-68.1M
↑ 30.21%
Investing Cash Flow
35.6M
↑ 1896.8%
Financing Cash Flow
236.5M
↑ 473.1%
FY19Y/Y Change
Operating Cash Flow
-69.1M
↑ 1.47%
Investing Cash Flow
-35.9M
↓ 200.7%
Financing Cash Flow
-3.9M
↓ 101.63%
FY20Y/Y Change
Operating Cash Flow
-80.3M
↑ 16.08%
Investing Cash Flow
-54.3M
↑ 51.49%
Financing Cash Flow
27.3M
↓ 807.46%
FY21Y/Y Change
Operating Cash Flow
-104.6M
↑ 30.28%
Investing Cash Flow
7.3M
↓ 113.39%
Financing Cash Flow
47.5M
↑ 73.94%
FY22Y/Y Change
Operating Cash Flow
-87.4M
↓ 16.37%
Investing Cash Flow
-2.8M
↓ 137.93%
Financing Cash Flow
1.1M
↓ 97.59%
Q2 FY22Q/Q Change
Operating Cash Flow
-23.6M
↓ 35.62%
Investing Cash Flow
-1.6M
↑ 58.35%
Financing Cash Flow
2.6M
↓ 65.74%
Q3 FY22Q/Q Change
Operating Cash Flow
-26.0M
↑ 10.5%
Investing Cash Flow
-61.0K
↓ 96.08%
Financing Cash Flow
-4.1M
↓ 256.65%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.2M
↓ 95.32%
Investing Cash Flow
-1.8M
↑ 2831.15%
Financing Cash Flow
-5.0M
↑ 22.38%
Q1 FY23Q/Q Change
Operating Cash Flow
-28.3M
↑ 2221.8%
Investing Cash Flow
-1.8M
↑ 0.0%
Financing Cash Flow
19.8M
↓ 492.3%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.0M
↓ 32.77%
Investing Cash Flow
-1.8M
↑ 0.0%
Financing Cash Flow
19.8M
↑ 0.19%

Technicals Summary

Sell

Neutral

Buy

Cellectis S.a. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cellectis S.a.
Cellectis S.a.
1.54%
149.5%
35.74%
-86.93%
-86.74%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cellectis S.a.
Cellectis S.a.
NA
NA
0.0
-1.27
-0.71
-0.19
NA
1.37
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cellectis S.a.
Cellectis S.a.
Buy
$190.0M
-86.74%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • Long Focus Capital Management, LLC

    6.25%

  • Capital Research & Mgmt Co - Division 3

    2.58%

  • Credit Suisse First Boston (CSFB)

    2.00%

  • Baillie Gifford & Co Limited.

    1.14%

  • Principal Financial Group Inc

    0.56%

  • Macquarie Group Ltd

    0.32%

Corporate Announcements

  • Cellectis S.a. Earnings

    Cellectis S.a.’s price-to-earnings ratio stands at None

    Read More

Company Information

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Organization
Cellectis S.a.
Employees
231
CEO
Dr. Andre Choulika Ph.D.
Industry
Health Technology

Discover More

FAQs